NO2970700T3 - - Google Patents
Info
- Publication number
- NO2970700T3 NO2970700T3 NO14709546A NO14709546A NO2970700T3 NO 2970700 T3 NO2970700 T3 NO 2970700T3 NO 14709546 A NO14709546 A NO 14709546A NO 14709546 A NO14709546 A NO 14709546A NO 2970700 T3 NO2970700 T3 NO 2970700T3
- Authority
- NO
- Norway
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261736799P | 2012-12-13 | 2012-12-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO2970700T3 true NO2970700T3 (lt) | 2018-05-26 |
Family
ID=49943326
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO14709546A NO2970700T3 (lt) | 2012-12-13 | 2014-03-05 |
Country Status (44)
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105218482B (zh) * | 2014-06-24 | 2018-04-06 | 杭州和泽医药科技有限公司 | 沃替西汀氢溴酸盐β晶型的制备方法 |
| CN104610195B (zh) * | 2015-01-30 | 2017-06-27 | 上虞京新药业有限公司 | 沃替西汀的天冬氨酸盐或其水合物及其制备方法和用途 |
| CN105315184B (zh) * | 2015-06-26 | 2017-03-29 | 上海医药工业研究院 | 一种沃替西汀的制备方法及其中间体 |
| MX2018000657A (es) * | 2015-07-17 | 2018-09-06 | Pasteur Institut | Agente estimulador del receptor 5-hidroxi triptamina 1b para usarse como un promotor de la autorrenovación y/o diferenciación de células satélite. |
| CN105534933A (zh) * | 2016-01-19 | 2016-05-04 | 美吉斯制药（厦门）有限公司 | 一种沃替西汀口腔崩解片及其制备方法 |
| JP2019524682A (ja) | 2016-07-01 | 2019-09-05 | ハー・ルンドベック・アクチエゼルスカベット | 抗うつ作用の速い発現のためのボルチオキセチン投与計画 |
| US10398691B2 (en) | 2017-03-30 | 2019-09-03 | Rundle Research, LLC | Methods of treating depression |
| CA3048206C (en) * | 2017-03-30 | 2019-12-24 | Rundle Research, LLC | Transitioning patients from vortioxetine to a monoamine oxidase inhibitor |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK569087A (da) | 1986-10-31 | 1988-05-01 | Sumitomo Pharma | Quinolin-derivater, deres fremstilling og anvendelse |
| IT1225462B (it) | 1987-04-03 | 1990-11-14 | Mediolanum Farmaceutici Srl | Sali organici di derivati della fisostigmina |
| DE3856594D1 (de) | 1987-05-04 | 2008-11-27 | Bonnie Davis | Mittel zur behandlung der alzheimer-krankheit |
| EP0403713A1 (en) | 1989-06-22 | 1990-12-27 | Merrell Dow Pharmaceuticals Inc. | Novel acetylcholinesterase inhibitors |
| US4914102A (en) | 1989-09-28 | 1990-04-03 | Hoechst Roussel Pharmaceuticals, Inc. | N-aminocarbamates related to physostigmine, pharmacentical compositions and use |
| TW200462B (lt) | 1990-09-27 | 1993-02-21 | Hoechst Roussel Pharma | |
| US5246947A (en) | 1991-09-23 | 1993-09-21 | Hoechst-Roussel Pharmaceuticals Incorporated | Substituted pyridinylamino-1,2-benzisothiazoles and their use for treating depression |
| US5231093A (en) | 1991-10-01 | 1993-07-27 | Hoechst-Roussel Pharmaceuticals Incorporated | Carbamate derivatives of 4-amino-3-isoxazolidinones, 3-amino-1-hydroxypyrrolidin-2-ones and 1-amino-1-cyclopropanecarboxylic acid analogs |
| ES2042384B1 (es) | 1991-12-26 | 1994-06-01 | Boehringer Ingelheim Espana | Procedimiento para obtener derivados bis-piridinicos. |
| SE9302080D0 (sv) | 1993-06-16 | 1993-06-16 | Ab Astra | New compounds |
| IL126308A0 (en) | 1996-04-12 | 1999-05-09 | Hoechst Marion Roussel Inc | Isatin derivatives as acetylcholinesterase inhibitors and analgesics |
| UA81749C2 (uk) | 2001-10-04 | 2008-02-11 | Х. Луннбек А/С | Фенілпіперазинові похідні як інгібітори зворотного захоплення серотоніну |
| DE60318306T2 (de) | 2002-03-29 | 2008-12-11 | Eisai R&D Management Co., Ltd. | (1-indanon)-(1,2,3,6-tetrahydropyridin)derivat |
| MXPA04011762A (es) * | 2002-05-31 | 2005-03-31 | Lundbeck & Co As H | Una combinacion de antagonista de nmda e inhibidores de acetilcolinesterasa para el tratamiento de la enfermedad de alzheimer. |
| BR0317747A (pt) * | 2002-12-24 | 2005-11-22 | Neurochem Int Ltd | Método de tratamento terapêutico concomitante de um indivìduo, composição farmacêutica, kit, uso de um primeiro agente e um segundo agente, e, métodos de prevenir ou tratar uma doença relacionada com amilóide-b, doença de alzheimer e insuficiência cognitiva suave |
| IN266817B (lt) * | 2006-05-08 | 2015-06-03 | Teikoku Seiyaku Kk | |
| EP2026783A2 (en) * | 2006-06-09 | 2009-02-25 | Wyeth a Corporation of the State of Delaware | Method for enhancing cognitive function |
| PL2044043T5 (pl) | 2006-06-16 | 2022-05-02 | H. Lundbeck A/S | Bromowodorek 1-[2-(2,4-dimetylofenylosulfanylo)fenylo]piperazyny jako związek o połączonym działaniu wychwytu zwrotnego serotoniny i działaniu na 5-ht3 i 5-ht1a do leczenia upośledzenia funckji poznawczych |
| WO2009005519A1 (en) * | 2007-06-29 | 2009-01-08 | Accera, Inc. | Combinations of medium chain triglycerides and therapeutic agents for the treatment and prevention of alzheimer's disease and other diseases resulting from reduced neuronal metabolism |
| TW200932233A (en) * | 2007-11-13 | 2009-08-01 | Lundbeck & Co As H | Therapeutic uses of compounds having combined SERT, 5-HT3 and 5-HT1a activity |
| TW201033181A (en) | 2009-02-17 | 2010-09-16 | Lundbeck & Co As H | Purification of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine |
-
2013
- 2013-12-12 AU AU2013357308A patent/AU2013357308B2/en not_active Ceased
- 2013-12-12 NZ NZ708595A patent/NZ708595A/en not_active IP Right Cessation
- 2013-12-12 ME MEP-2018-66A patent/ME03029B/me unknown
- 2013-12-12 BR BR112015013675-3A patent/BR112015013675B1/pt not_active IP Right Cessation
- 2013-12-12 SG SG11201504483YA patent/SG11201504483YA/en unknown
- 2013-12-12 RU RU2015122256A patent/RU2635528C2/ru active
- 2013-12-12 HU HUE13818702A patent/HUE036280T2/hu unknown
- 2013-12-12 MY MYPI2015001479A patent/MY171802A/en unknown
- 2013-12-12 MX MX2015007269A patent/MX362886B/es active IP Right Grant
- 2013-12-12 CN CN201380065034.2A patent/CN104853755B/zh active Active
- 2013-12-12 SI SI201330970T patent/SI2931276T1/en unknown
- 2013-12-12 KR KR1020157015715A patent/KR102171152B1/ko active IP Right Grant
- 2013-12-12 PE PE2015000879A patent/PE20151026A1/es active IP Right Grant
- 2013-12-12 US US14/649,087 patent/US9211288B2/en active Active
- 2013-12-12 AR ARP130104651A patent/AR093939A1/es not_active Application Discontinuation
- 2013-12-12 EA EA201590932A patent/EA028300B1/ru not_active IP Right Cessation
- 2013-12-12 UA UAA201506381A patent/UA114016C2/uk unknown
- 2013-12-12 ES ES13818702.6T patent/ES2663680T3/es active Active
- 2013-12-12 JP JP2015547020A patent/JP6257641B2/ja active Active
- 2013-12-12 LT LTEP13818702.6T patent/LT2931276T/lt unknown
- 2013-12-12 PL PL13818702T patent/PL2931276T3/pl unknown
- 2013-12-12 PT PT138187026T patent/PT2931276T/pt unknown
- 2013-12-12 EP EP13818702.6A patent/EP2931276B1/en active Active
- 2013-12-12 AP AP2015008498A patent/AP2015008498A0/xx unknown
- 2013-12-12 CA CA2893468A patent/CA2893468C/en active Active
- 2013-12-12 RS RS20180285A patent/RS56949B1/sr unknown
- 2013-12-12 MA MA38253A patent/MA38253B1/fr unknown
- 2013-12-12 DK DK13818702.6T patent/DK2931276T3/en active
- 2013-12-12 WO PCT/EP2013/076337 patent/WO2014090929A1/en active Application Filing
- 2013-12-12 GE GEAP201313850A patent/GEP201706739B/en unknown
-
2014
- 2014-03-05 NO NO14709546A patent/NO2970700T3/no unknown
-
2015
- 2015-05-27 TN TNP2015000235A patent/TN2015000235A1/fr unknown
- 2015-06-03 DO DO2015000133A patent/DOP2015000133A/es unknown
- 2015-06-03 IL IL239192A patent/IL239192B/en active IP Right Grant
- 2015-06-08 PH PH12015501302A patent/PH12015501302A1/en unknown
- 2015-06-08 GT GT201500143A patent/GT201500143A/es unknown
- 2015-06-09 EC ECIEPI201523182A patent/ECSP15023182A/es unknown
- 2015-06-09 NI NI201500078A patent/NI201500078A/es unknown
- 2015-06-09 CR CR20150303A patent/CR20150303A/es unknown
- 2015-06-10 CL CL2015001615A patent/CL2015001615A1/es unknown
- 2015-06-12 ZA ZA2015/04274A patent/ZA201504274B/en unknown
-
2016
- 2016-01-18 HK HK16100513.0A patent/HK1212601A1/zh unknown
-
2018
- 2018-02-23 HR HRP20180333TT patent/HRP20180333T1/hr unknown
- 2018-03-27 CY CY20181100347T patent/CY1120098T1/el unknown
-
2022
- 2022-05-19 AR ARP220101337A patent/AR125920A2/es unknown